BeyondSpring shares surge 32.52% premarket on positive DUBLIN-3 trial results for Plinabulin + docetaxel in NSCLC.

Beyondspring (NASDAQ: BYSI) surged 32.52% in premarket trading following the announcement of positive post-hoc analyses from its DUBLIN-3 Phase 3 trial. The data showed that Plinabulin plus docetaxel improved median overall survival (OS) to 15.8 months versus 11.7 months with docetaxel alone (HR=0.55), along with significant gains in progression-free survival (PFS) and objective response rate (ORR). The combination also reduced grade 4 neutropenia and new brain metastases, positioning Plinabulin as a potential new standard of care for non-squamous EGFR wild-type NSCLC patients resistant to anti-PD-(L)1 therapy. Beyondspring plans to initiate the global confirmatory Phase 3 DUBLIN-4 trial, reinforcing the drug’s clinical and commercial potential. The results, presented at major oncology conferences and highlighted in Asian subsets, underscored the therapy’s differentiated safety profile and durable benefits, driving the sharp premarket increase.